Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome
Authors:
- 1 October 2011
- journal article
- Published by Springer Nature in Pediatric Nephrology
- Vol. 26 (10) , 1823-1828
Abstract
Rituximab (RTX) has a significant steroid-sparing effect in children with steroid-dependent nephrotic syndrome (SDNS). However, patients are likely to relapse with the recovery of CD20+ cells. We conducted a small prospective cohort study with a historical control to evaluate the effect of RTX infusion followed by mycophenolate mofetil (MMF) as a maintenance therapy. Nine patients with SDNS who stopped their steroid treatment but were treated with MMF after RTX infusion were prospectively observed (group A). Seven patients with SDNS who discontinued steroid and immunosuppressive agents after RTX administration served as a control (group B). During the first year after the administration of RTX, six patients in group A and one patient in group B did not suffer a relapse (p < 0.05). The number of patients who relapsed during the 1 year preceding RTX treatment did not differ between the two groups [4.1 (A) vs. 5.7 (B)], but it was significantly lower in the MMF-treated group 1 year after the RTX treatment [0.4 (A) vs. 2.3 (B), p < 0.005]. The daily amount of prednisolone after the RTX treatment was lower in group A than in group B (0.11 vs. 0.46 mg/kg/day, respectively; p < 0.05). Three patients in group A and five patients in group B relapsed to SDNS and needed additional RTX treatment(s) within 1 year (odds ratio 5.0). Based on these results, we conclude that maintenance therapy with MMF after RTX is a good clinical option.Keywords
This publication has 17 references indexed in Scilit:
- Rituximab efficiency in children with steroid-dependent nephrotic syndromePediatric Nephrology, 2010
- Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporinePediatric Nephrology, 2010
- Long-Term Outcome of Biopsy-Proven, Frequently Relapsing Minimal-Change Nephrotic Syndrome in ChildrenClinical Journal of the American Society of Nephrology, 2009
- Rituximab (B‐cell depleting antibody) associated lung injury (RALI): A pediatric case and systematic review of the literaturePediatric Pulmonology, 2009
- Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in childrenPediatric Nephrology, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndromePediatric Nephrology, 2005
- Change of the course of steroid-dependent nephrotic syndrome after rituximab therapyPediatric Nephrology, 2004
- GONADAL FUNCTION IN BOYS WITH STEROID-RESPONSIVE NEPHROTIC SYNDROME TREATED WITH CYCLOPHOSPHAMIDE FOR SHORT PERIODSThe Lancet, 1981
- The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisoneThe Journal of Pediatrics, 1981